310 related articles for article (PubMed ID: 21912486)
1. Contrast-induced nephropathy in interventional cardiology.
Sudarsky D; Nikolsky E
Int J Nephrol Renovasc Dis; 2011; 4():85-99. PubMed ID: 21912486
[TBL] [Abstract][Full Text] [Related]
2. Contrast-induced nephropathy: epidemiology and prevention.
Bagshaw SM; Culleton BF
Minerva Cardioangiol; 2006 Feb; 54(1):109-29. PubMed ID: 16467746
[TBL] [Abstract][Full Text] [Related]
3. Reducing the risks for contrast-induced nephropathy.
Stacul F
Cardiovasc Intervent Radiol; 2005; 28 Suppl 2():S12-8. PubMed ID: 16419278
[TBL] [Abstract][Full Text] [Related]
4. Contrast nephropathy in children.
Verghese PS
J Pediatr Intensive Care; 2014 Jun; 3(2):45-52. PubMed ID: 31214451
[TBL] [Abstract][Full Text] [Related]
5. Prevention of contrast-induced nephropathy in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review.
Busch SV; Jensen SE; Rosenberg J; Gögenur I
J Interv Cardiol; 2013 Feb; 26(1):97-105. PubMed ID: 23240788
[TBL] [Abstract][Full Text] [Related]
6. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial.
Hölscher B; Heitmeyer C; Fobker M; Breithardt G; Schaefer RM; Reinecke H
Can J Cardiol; 2008 Nov; 24(11):845-50. PubMed ID: 18987758
[TBL] [Abstract][Full Text] [Related]
7. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
[TBL] [Abstract][Full Text] [Related]
8. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
9. Contrast-induced nephropathy: a review.
Sanaei-Ardekani M; Movahed MR; Movafagh S; Ghahramani N
Cardiovasc Revasc Med; 2005; 6(2):82-8. PubMed ID: 16263365
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
[TBL] [Abstract][Full Text] [Related]
11. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
[TBL] [Abstract][Full Text] [Related]
12. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
Boccalandro F; Amhad M; Smalling RW; Sdringola S
Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
15. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
[TBL] [Abstract][Full Text] [Related]
16. Strategies to reduce the risk of contrast-induced nephropathy.
Stacul F; Adam A; Becker CR; Davidson C; Lameire N; McCullough PA; Tumlin J;
Am J Cardiol; 2006 Sep; 98(6A):59K-77K. PubMed ID: 16949381
[TBL] [Abstract][Full Text] [Related]
17. [Contrast induced nephropathy].
Hörl WH
Wien Klin Wochenschr; 2009; 121(1-2):15-32. PubMed ID: 19263010
[TBL] [Abstract][Full Text] [Related]
18. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine.
Chong E; Poh KK; Liang S; Tan HC
Ann Acad Med Singap; 2010 May; 39(5):374-80. PubMed ID: 20535427
[TBL] [Abstract][Full Text] [Related]
20. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography.
Calabrò P; Bianchi R; Crisci M; Caprile M; Bigazzi MC; Palmieri R; Golia E; De Vita A; Romano IJ; Limongelli G; Russo MG; Calabrò R
Intern Emerg Med; 2011 Dec; 6(6):503-7. PubMed ID: 21279477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
